the principal pregnancy registries suggest that AEDs differ in their teratogenic risk. For example, data from the North American AED Pregnancy Registry (NAAPR) and the International Registry of Antiepileptic Drugs in Pregnancy (EURAP) place lamotrigine and levetiracetam among the AEDs with the lowest rates of major congenital malformations at 2.0 to 2.9 percent and 1.6 to 2.4 percent, respectively (2, 3) . This is in contrast to the findings for valproic acid, which suggest that this AED is associated with one of the highest rates of major congenital malformations at 9.3 to 9.7 percent (2, 3). Also a publication from the EURAP team reported a correlation between the dose at the time of conception and the risk of major congenital malformations for lamotrigine, carbamazepine, phenobarbital, and valproate (2) . Similar findings were published by members of the Australian Pregnancy Register demonstrating dose dependence of fetal malformations associated with valproate as well as with topiramate in combination therapy (4, 5) . Clearly, the different pregnancy registries have yielded an impressive amount of consistent data, which for the most part provide guidance to clinicians treating women of reproductive age suffering from epilepsy.
Simultaneous to the development of pregnancy registries, there have been groundbreaking studies on the OBJECTIVE: To evaluate the effects of epilepsy and antiepileptic drugs (AEDs) used during pregnancy on fetal growth and preterm delivery. METHODS: This study included singleton liveborn infants born to women enrolled in the North American Antiepileptic Drug Pregnancy Registry between 1997 and 2016. Data were collected prospectively through telephone interviews. The prevalence of preterm birth (<37 weeks) and small for gestational age status (SGA) among infants exposed prenatally to AEDs when used by women with epilepsy (WWE) or women without epilepsy (WWOE) was compared with that among infants unexposed to AEDs and born to WWOE. Multivariate log-binomial regression models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs). RESULTS: The study population included infants born to 6,777 AED-WWE, 696 AED-WWOE, and 486 no-AED-WWOE. The risk of prematurity was 6.2% for no-AED-WWOE, 9.3% for AED-WWE (RR = 1.5, 95% CI = 1.0-2.1), and 10.5% for AED-WWOE (RR = 1.5, 95% CI = 1.0-2.4). Prenatal exposure to AEDs in WWE and WWOE was associated with a mean lower birth weight of 110 and 136g, respectively, as compared to no-AED-WWOE. The prevalence of SGA was 5.0% for no-AED-WWOE, 10.9% for AED-WWE(RR = 2.0, 95% CI = 1.3-3.0), and 11.0% for AED-WWOE (RR = 1.9, 95% CI = 1.2-2.9). Within users of AEDs in monotherapy, the prevalence of SGA ranged from 7.3% for lamotrigine to 18.5% for topiramate. INTERPRETATION: Women on AEDs during pregnancy, whether for epilepsy or for other neuropsychiatric indications, are at a higher risk of delivering prematurely and giving birth to SGA newborns. The risk may vary by drug.
More Than Meets the Eye: Antiepileptic Drug Use During Pregnancy and its Effects Beyond Teratogenesis
subject of cognitive teratogenesis associated with AEDs. For example, in the prospective Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study, children who had been exposed to valproate in utero had significantly lower intelligence quotient (IQ) scores (up to 10 points lower) than those exposed to other AEDs, after adjustment for maternal IQ among other factors (6) . In addition, some detrimental neurobehavioral effects of AEDs have been unveiled, most notably the risk of autism spectrum disorders with fetal exposure to valproate. In fact, a prospective, populationbased birth cohort study from Denmark showed absolute risks of 2.5 and 4.4 percent for autism and autism spectrum disorder, respectively.
While there has been a steady flow of new information about the teratogenic potential of AEDs, the perinatal outcomes and obstetrical complications in women with epilepsy have not been as well delineated. Remote studies suggested a higher percentage of obstetrical complications, such as pre-eclampsia and poorer fetal outcomes, with growth restriction in this population (8) . However, there has been some controversy about the relevance and etiology of these findings, with some attributing them to the use of AEDs, and others to breakthrough seizures during pregnancy. Data on the obstetrical and perinatal outcomes of women with epilepsy had been scarce and unclear until the last 10 years or so. A retrospective study found that seizures during pregnancy were associated with a 1.36-1.63-, and 1.37-fold increased risk of low-birth-weight infants, preterm delivery, and small for gestational age (SGA), respectively (9) . A secondary analysis of the neonatal outcomes from the NEAD cohort reported that adverse neonatal outcome risks may differ among the AEDs; the odds ratio for infants being born SGA was higher for the valproate and carbamazepine groups, and reduced 1-minute Apgar scores occurred more frequently in the phenytoin and valproate groups (10) . In 2014, a publication from the NAAPR suggested an association between in utero exposure to zonisamide and topiramate and a decrease in mean birth weight and length.
The most recent contribution from the NAAPR that investigated fetal growth and premature delivery is the subject of this commentary. The data provide detailed prospective data from a large cohort of infants born to 6777 woman with epilepsy (WWE) on AEDs, 696 born to woman without epilepsy (WWoE) on AEDs, and 486 controls. Among women on AEDs, 0.7% pregnancies resulted in stillbirth or neonatal death compared with 0.2% in the unexposed group. The mean birth weight for the reference group was 3453 g; compared with these unexposed pregnancies, prenatal exposure to AEDs was associated with a mean lower birth weight of 110 g among WWE and 136 g among WWoE (P < 0.01). The mean infant's height at birth for unexposed women was 51.1 cm; and use of AEDs was associated with a mean height reduction of 0.5 cm for both WWE and WWoE (P < 0.01). There was a higher proportion of preterm deliveries in women who used AEDs, with 9.3% in WWE, 10.5% in WWoE, and 6.2% in the reference group. After adjustment for measured cofounders the relative risk (RR) was 1.5 (95% CI 1-2.1) and 1.5 (95% CI 1.0-2.4) for WWE and WWoE, respectively. The prevalence for SGA was 5.0% for the unexposed group, and on AED users it was 10.9% within WWE and 11.0% in WWoE. After adjustment for measured cofounders, the RR was 2.0 (95% CI 1.3-3.0) and 1.9 (95% CI 1.2-2.9) for WWE and WWoE, respectively. The prevalence of SGA was different for different drugs, with topiramate, phenobarbital, and zonisamide monotherapies presenting the highest risks. Similar results for birth weight, height, preterm deliveries and SGA in all women on AEDs independently of the presence of epilepsy, as well as the significant difference between both of these groups and the reference subjects in all analyses, suggest that these findings are in fact related to the use of AEDs. Among WWE on AEDs, having seizures and being on polytherapy, were associated with worse pregnancy outcomes.
Being born preterm and SGA have been associated with worse health outcomes in the perinatal period, and also later in life. This study provides definite evidence on important obstetrical and perinatal outcomes that need to be taken into consideration when taking decisions on how to treat and counsel women of childbearing potential with epilepsy. More studies are needed to understand the full extent of these risks with the use of AEDs. It is expected that pregnancy registries and prospective projects like the Maternal Outcomes and Neurodevelopmental Effects of AEDs study will continue to shed light on the consequences of treatment with AEDs during pregnancy.
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